Share on LinkedInShare on LinkedIn

ARTICLE · 06 JANUARY 2026

Diagnostics And Antimicrobial Stewardship: Patent Trends And Policy Implications

Marks & Clerk
Marks & Clerk
Contributor
Marks & Clerk

Marks & Clerk

Marks & Clerk LLP was founded in 1887 by George Croydon Marks, who was joined in partnership by...

View firm profile
Explore more from Marks & Clerk

A 2024 peer-reviewed study surveyed 300 healthcare professionals' across six countries to understand barriers and opportunities in diagnostic testing and antimicrobial stewardship.

United KingdomIntellectual Property

Introduction

A 2024 peer-reviewed study (here) surveyed 300 healthcare professionals' (HCPs) across six countries to understand barriers and opportunities in diagnostic testing and antimicrobial stewardship (AMS). AMS is a systematic approach to support clinicians in prescribing and administering antimicrobials according to evidence‑based guidelines.

The study found that economic constraints—insufficient investment, limited resources, and patient or institutional costs—were the primary obstacles to effective diagnostic utilisation. Additional challenges included slow test turnaround times, high antimicrobial resistance (AMR) burden, and gaps in education and guidelines. Notably, most respondents agreed that improved diagnostics reduce AMR (70.3%) and improve patient outcomes (81.0%).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from